Search "peptides for injury healing" in the Philippines and three names come up repeatedly: BPC-157, TB-500 and GHK-Cu, often sold together as the GLOW blend. None is an approved medicine. The evidence behind all three comes almost entirely from rats, mice and cells in a dish, not from people with actual tendon, ligament or muscle injuries. This guide lays out what has actually been published, ranked by the strength of that evidence rather than by how often a compound is mentioned online.
Summary
| Compound | Best evidence | Stage |
|---|---|---|
| BPC-157 Stocked locally | Rat tendon, ligament and tendon-outgrowth studies from a Croatian research group | Animal and cell only; no published human trials |
| TB-500 Stocked locally | Rat Achilles tendon healing, including a 2026 study comparing it directly with BPC-157 | Animal only for the marketed fragment; human wound trials exist only for the different, full-length parent molecule |
| GHK-Cu (injectable) Stocked locally | Rat and rabbit wound-contraction and collagen studies | Animal and cell only; human evidence exists only for the topical form |
BPC-157: the most studied, entirely in animals
BPC-157 is a synthetic 15-amino-acid fragment derived from a protective protein found in gastric juice. It was discovered and is still studied almost exclusively by a research group in Zagreb, led by Predrag Sikiric, which has published dozens of rat studies covering the gut, tendons, ligaments, muscle and more.
The soft-tissue evidence most relevant to injury healing includes:
- Staresinic and colleagues (2003) surgically transected the Achilles tendon in rats, treated some with BPC-157, and also grew rat tendon cells in culture with the peptide. The paper reports the peptide accelerated tendon healing in the rats and stimulated tendon-cell growth in the dish.
- Cerovecki and colleagues (2010) studied ligament healing in rats using the same peptide.
- Chang and colleagues (2011) looked more closely at the biology, reporting that BPC-157 affected tendon cell outgrowth, survival and migration in tendon explant and cell-culture experiments.
Every one of these is animal or cell work. We could not find a single published trial of BPC-157 in human patients with a tendon, ligament or muscle injury. Anyone using it for that purpose is extrapolating from rodent results.
TB-500: a fragment of a molecule with some human wound data
TB-500 is sold on the research market as a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell movement, wound closure and inflammation. The US FDA's own list of compounding safety-risk substances refers to it under a "thymosin beta-4 fragment" entry, which is a useful clue to how it differs from the parent molecule.
A 2026 rat study by Bicer and colleagues compared BPC-157, TB-500 and a combination of the two on Achilles tendon healing, using histopathology and biomechanical testing. It is a direct head-to-head in the same animal model, which is unusual for this space, though it is one study and, like the BPC-157 literature, entirely in rats.
Separately, the full-length, 43-amino-acid parent protein, thymosin beta-4, has been tested in people, but for skin wounds rather than tendons: an eight-site European study by Guarnera and colleagues (2010) looked at it as a treatment for venous leg ulcers, and a 2012 paper by Treadwell and colleagues describes it accelerating dermal healing in both animal models and patients. Both used topical or gel formulations of the full protein, not the injectable fragment sold as TB-500, so they do not tell you what the research-market product does in a strained tendon or torn muscle.
GHK-Cu (injectable): wound biology, not injury biology
Injectable GHK-Cu is the same copper-binding tripeptide sold in skincare, repackaged as a research vial. The 2018 review by Pickart and Margolina, who discovered the peptide, summarises animal wound-healing work: improved wound contraction and granulation tissue in rabbits, faster healing with GHK-containing collagen dressings in rats, including one preparation that raised wound collagen ninefold, and better outcomes in rats with poor-blood-supply wounds.
That is wound-repair biology, closer to skin healing than to tendon or ligament repair, and it is animal work applied directly to open wounds or dressings, not a model of a subcutaneous injection near an injured joint. No published human trial of injected GHK-Cu exists. The human data for GHK-Cu is entirely from topical creams; see GHK-Cu (topical) for that separate evidence base.
Why animal-only evidence is worth treating carefully
Rats are not people, and a compound that speeds tendon healing in a rodent model does not automatically do the same in a human tendon under mechanical load, different immune signalling and years of accumulated wear. Translating a finding from animal injury models into a working human treatment is a well-known failure point in orthopaedic and wound research generally, which is one reason drug development for musculoskeletal injuries takes years of further human testing even after promising animal results. None of BPC-157, TB-500 or injectable GHK-Cu has reached that further stage.
The GLOW blend is not a shortcut
GLOW packages GHK-Cu, BPC-157 and TB-500 into a single vial, usually split 50/10/10 mg, and is marketed for tissue repair generally. No study has tested the three together. Buying the blend does not add evidence; it adds three unstudied combinations of doses instead of one, and the ratio itself is a supplier's choice rather than anything derived from research.
Safety and sourcing
None of these three has a controlled human safety record for injection. The cosmetic literature on GHK-Cu spans decades without reported problems, but that applies to creams, not injections. Contamination and reconstitution errors are the practical risks that are well documented, regardless of what the peptide itself might do; see sourcing principles and side effect management. If you are tracking bloodwork alongside anything you inject, bloodwork in the Philippines covers what is worth testing and why.
Status in the Philippines
BPC-157, TB-500 and injectable GHK-Cu are not registered with FDA Philippines as medicines and are not approved anywhere else. None is a scheduled controlled substance under RA 9165. All three are sold locally only through research-chemical suppliers.
